Abstract:Background & Aims: Chronic liver injury often results in the activation of hepatic myofibroblasts and the development of liver fibrosis. Hepatic myofibroblasts may originate from 3 major sources: hepatic stellate cells (HSCs), portal fibroblasts (PFs), and fibrocytes, with varying contributions depending on the etiology of liver injury. Here, we assessed the composition of hepatic myofibroblasts in multidrug resistance gene 2 knockout (Mdr2(-/-)) mice, a genetic model that resembles primary sclerosing cholangitis in patients. Methods: Mdr2(-/-) mice expressing a collagen-GFP reporter were analyzed at different ages. Hepatic non-parenchymal cells isolated from collagen-GFP Mdr2(-/-) mice were sorted based on collagen-GFP and vitamin A. An NADPH oxidase (NOX) 1/4 inhibitor was administrated to Mdr2(-/-) mice aged 12-16 weeks old to assess the therapeutic approach of targeting oxidative stress in cholestatic injury. Results: Thy1(+) activated PFs accounted for 26%, 51%, and 54% of collagen-GFP(+) myofibroblasts in Mdr2(-/-) mice at 4, 8, and 16 weeks of age, respectively. The remaining collagen-GFP(+) myofibroblasts were composed of activated HSCs, suggesting that PFs and HSCs are both activated in Mdr2(-/-) mice. Bone-marrow-derived fibrocytes minimally contributed to liver fibrosis in Mdr2(-/-) mice. The development of cholestatic liver fibrosis in Mdr2(-/-) mice was associated with early recruitment of Gr1(+) myeloid cells and upregulation of pro-inflammatory cytokines (4 weeks). Administration of a NOX inhibitor to 12-week-old Mdr2(-/-) mice suppressed the activation of myofibroblasts and attenuated the development of cholestatic fibrosis. Conclusions: Activated PFs and activated HSCs contribute to cholestatic fibrosis in Mdr2(-/-) mice, and serve as targets for antifibrotic therapy. Lay summary: Activated portal fibroblasts and hepatic stellate cells, but not fibrocytes, contributed to the production of the fibrous scar in livers of Mdr2(-/-) mice, and these cells can serve as targets for antifibrotic therapy in cholestatic injury. Therapeutic inhibition of the enzyme NADPH oxidase (NOX) in Mdr2(-/-) mice reversed cholestatic fibrosis, suggesting that targeting NOXs may be an effective strategy for the treatment of cholestatic fibrosis. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver

CXCL6-EGFR-induced Kupffer Cells Secrete TGF-beta 1 Promoting Hepatic Stellate Cell Activation Via the SMAD2/BRD4/C-MYC/EZH2 Pathway in Liver Fibrosis

Distribution of kupffer and hepatic stellate cells during spontaneous reversible carbon-tetrachloride-induced liver fibrosis in rats

Activated Hepatic Stellate Cells and Portal Fibroblasts Contribute to Cholestatic Liver Fibrosis in MDR2 Knockout Mice

Mangiferin Ameliorates CCl4-Triggered Acute Liver Injury by Inhibiting Inflammatory Response and Oxidative Stress: Involving the Nrf2-ARE Pathway

Impaired Balance of T Helper 17/T Regulatory Cells in Carbon Tetrachloride-Induced Liver Fibrosis in Mice

Hepatocyte-specific Deficiency of Nrf2 Exacerbates Carbon Tetrachloride-Induced Liver Fibrosis Via Aggravated Hepatocyte Injury and Subsequent Inflammatory and Fibrogenic Responses.

Collagen-binding Vascular Endothelial Growth Factor Attenuates CCl4-induced Liver Fibrosis in Mice

C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape

Inhibition of the Translocation and Extracellular Release of High-Mobility Group Box 1 Alleviates Liver Damage in Fibrotic Mice in Response to D-galactosamine/lipopolysaccharide Challenge

Involvement of the Nuclear High Mobility Group B1 Peptides Released from Injured Hepatocytes in Murine Hepatic Fibrogenesis.

Differential recruitment of monocyte‐derived macrophages in control and stellate cell‐depleted mice during recurrent carbon tetrachloride‐induced acute liver injury

Contribution and Mobilization of Mesenchymal Stem Cells in a Mouse Model of Carbon Tetrachloride-Induced Liver Fibrosis

Taurocholic Acid Promotes Hepatic Stellate Cell Activation Via S1PR2/p38 MAPK/YAP Signaling under Cholestatic Conditions

Loss of steroid receptor co-activator-3 attenuates carbon tetrachloride-induced murine hepatic injury and fibrosis

Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment

Montelukast prevents mice against carbon tetrachloride- and methionine-choline deficient diet-induced liver fibrosis: Reducing hepatic stellate cell activation and inflammation

Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell–Mediated Hepatitis Via Compensatory Up-regulation of CXCR2–Related Chemokine Activity

Protective Effects of Curcumin Against Hepatic Fibrosis Induced by Carbon Tetrachloride: Modulation of High-Mobility Group Box 1, Toll-Like Receptor 4 and 2 Expression